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Abstract
Purpose To describe the characteristics and outcomes of pa-
tients presenting with rhegmatogenous retinal detachment
(RRD) after ocriplasmin (OCP) injection.
Methods Retrospective, multi-centre, observational case se-
ries with case note review.
Results Eight patients with symptomatic vitreomacular trac-
tion (six with concomitant macular hole) were diagnosed with
RRD after a median of 16 days (range 3–131 days) post-OCP
injection. Presentation was within 3 weeks of the OCP injec-
tion in six of the cases. Five patients presented with symptoms
post-OCP, and three were diagnosed asymptomatically on
planned visits. Seven cases were phakic, one had high myopia
(>8 dioptres), and two cases had lattice degeneration.
Following RRD surgery, hole closure was achieved in 5/6
MH cases. The final median BCVA at 7 months was 20/80
(range 20/40–20/1200) similar to the baseline BCVA 20/80,
with four patients gaining ≥1 line of vision compared to base-
line but three losing ≥3 lines.
Conclusions RRD is a non-negligible risk associated with in-
travitreal OCP, and it should be used with caution in eyes with
high myopia and peripheral retinal pathology predisposing to
RRD. Detailed peripheral retinal examination is recommend-
ed pre- and postoperatively at all visits. Patients should be
advised to seek attention if symptoms recur after initial
presentation.
Keywords Macular hole . Ocriplasmin . Pharmacological
vitreolysis .Retinal detachment .Retinal tears .Vitreomacular
traction
Introduction
Ocriplasmin (OCP) (Jetrea, Thrombogenics, The Netherlands)
has been licensed as a non-surgical treatment for symptomatic
vitreomacular traction (VMT). It is a recombinant truncated
form of human plasmin, and its chief mechanism of action is
thought to be by the cleavage of peptide bonds in the
vitreoretinal adhesion molecules laminin and fibronectin [1–3].
This action coupled with activation of endogenous matrix
metalloproteinase-2 is thought to result in its ability to precipitate
vitreoretinal separation [4]. Rhegmatogenous retinal detachment
(RRD) has been reported after OCP injection, albeit as an infre-
quent occurrence, with an incidence of 0.4 % (2/465) of the
OCP-treated patients in the pivotal microplasmin for intravitre-
ous injection-traction release without surgical treatment (MIVI-
TRUST) trials [5]. We report a series of eight RRD occurring
after OCP injection, and describe their characteristics and out-
comes following surgery.
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Method
In October 2014, the British and Eire Association of
Vitreoretinal Surgeons (BEAVRS) organised an email survey
of their members self-reporting their initial experiences with
intravitreal OCP. The survey consisted of a short data-
collection form on the number of patients treated with OCP,
the indications for treatment, success rates in terms of VMT
release and macular hole (MH) closure, as well as a list of
possible observed adverse effects including retinal tears and
detachments. Seven respondents reported eight patients with
tears/retinal detachment, and these consultant vitreoretinal
surgeons were then contacted with a more detailed data-
collection questionnaire concerning their cases that are pre-
sented here. Snellen visual acuities were converted to
logMAR for analysis. Under UK guidelines the study was
classified as a service evaluation by the local ethics commit-
tee, and as such did not require formal ethical approval.
Results
The initial email questionnaire collected data from a total of
241 OCP treated patients (241 eyes) by 41 surgeons. The
indication for treatment was MH with vitreomacular adhesion
(VMA) in 111 patients (46 %) and VMTalone in 130 (54 %).
Eight patients were reported by seven surgeons with retinal
tears and/or RRD following OCP. These surgeons were then
sent a second questionnaire with a detailed data-collection
form for each of the eight reported cases.
Baseline findings prior to OCP injection
Themean age of the eight patients was 63 years old (range 51–
76 years), and six (75 %) were female. The majority of cases
were phakic (88 %) at the time of the procedure. The mean
spherical equivalence was −3 dioptres (range −0.25 to −9
dioptres). The initial indication for OCP was VMT in two
cases (25 %) and MH with VMA adhesion in six (75 %).
The MH size was small (≤250 μm) in two eyes and medium
(250–400 μm) in four eyes, with a mean minimum linear
diameter of 276.8 μm (range, 192–380 μm). The mean dura-
tion of symptoms prior to OCP injection was 2 months (range,
0.75–10 months). The mean best-corrected visual acuity
(BCVA) at baseline was 20/80 (range 20/40–20/400).
Outcome summary
OCP was administered as per the manufacturer’s instructions
by a single 0.1 ml intravitreal injection of 125 micrograms
using a 30-g needle in all cases, with no immediate
injection-related complications noted. Experienced retinal sur-
geons in specialized eye units carried out all injections. The
RRD was diagnosed after a median of 16 days (range, 3–
131 days) post-OCP injection. Five of the patients reported
symptoms of photopsia starting within a few hours of injection
and lasting up to 72 h. One patient presented with RRD during
this phase on day 3. Four patients developed new symptoms
of floaters and photopsia after this period, and presented
symptomatically outside of scheduled appointments on days
6, 14, 18 and 20. Three patients were diagnosed asymptomat-
ically at scheduled appointments on days 5 and 54 post-pro-
cedure, and day 131 at the time of planned vitrectomy surgery
for a persistently open MH. In the 4/8 cases that were exam-
ined before presentation with RRD, VMA resolution was doc-
umented in two MH cases (25 %), and one (12.5 %) had
developed a posterior vitreous detachment (PVD) from the
optic disc head.
The findings at the time of RRD and surgical procedure
performed are described in Fig. 1. Four of the cases were mac-
ula on and four macula off at presentation. At the time of the
RRD repair, VMT resolution was noted in all cases, and PVD
with a Weiss ring in 7/8 cases. All the cases had one or more
superior tears. Cases 2 and 6 had additional tears at the 9 and 3
o’clock meridians respectively, and case 4 had an additional
inferior tear and associated detachment. In cases 2, 3 and 7,
the tears were located in the mid-periphery posterior to the
equator, whilst in the other five cases the tears were more pe-
ripheral at the posterior border of the vitreous base between the
equator and ora serrata. The distribution of breaks showed no
predilection for any one quadrant (Chi square test, p = 0.38).
Cases 1 and 6 developed a re-detachment at 4 and 2 weeks
post-primary RRD repair respectively. Case 1 was noted to
have recurrent retinal detachment at 4 weeks post-initial
RRD repair with early proliferative vitreoretinopathy infero-
temporally, with a new retinal tear in the same area. Revision
pars plana vitrectomy (PPV) combined with epiretinal mem-
brane peeling, cryotherapy, and 25 % SF6 gas injection was
performed successfully. At 6 months postoperatively the VA
was 20/80, and retina was attached. Case 6 developed a total
recurrent macula-off RRD with new tears at the 2-week fol-
low-up visit after initial PPV, and required a revision proce-
dure with laser and 14% C3F8 gas. This case was then treated
successfully for possible endophthalmitis 4 months later fol-
lowing uncomplicated cataract surgery with intravitreal anti-
biotics. The final VA at 14 months post RRD surgery and after
cataract surgery was 20/40. Both of these cases had areas of
lattice degeneration present.
All cases with MH had internal limiting membrane peeling
performed at the time of vitrectomy surgery for the RRD; and
following surgery, hole closure was achieved in 5/6MH cases.
The mean BCVA at 2 months post-OCP was 20/240 (range
20/40–20/1200). The final mean BCVA at a mean follow-up
of 8 months (range 5–14 months) was 20/80 (range 20/40–20/
1200), similar to the baseline BCVA. BCVA remained un-
changed in one patient, and four patients gained ≥ 1 line in
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vision compared with pre -OCPBCVA. Three patients lost ≥ 3
lines in VA, although one of these cases was still awaiting
cataract surgery at the time of data collection and subsequently
died secondary to bowel cancer.s
Discussion
We report the presentation and characteristics of eight cases of
RRD following OCP, representing the largest series of cases to
date. We are unable to give an incidence rate of RRD after
OCP, as we do not know the true denominator of cases treated
by members during the study period nor the completeness of
case reporting to us. As well as the 0.4 % rate in the phase 3
studies of OCP [1], a single case (representing 1.7 %) was
reported in the phase I MIVI study day 1 post-injection [3].
There have been reports of three cases of RRD [6–8] out of
213 [6–14] treated cases (1.4 %) in recent retrospective insti-
tutional studies, two of which occurred at day 6 and one at
week 6 post-OCP injection.
The mean age of 72 years in the MIVI trials was similar to
our cases. The majority of our cases were phakic (88 %) as
opposed to 63 % in the MIVI OCP group. One of our cases
had high myopia, which would have been excluded from the
phase 3MIVI trials, which had a cut off point of −8 dioptres of
myopia. Two of the patients also had lattice degeneration.
There have also been reports of two other patients with lattice
degeneration who developed RRD after OCP in recent insti-
tutional reviews [7, 8]. This was not listed as an exclusion
criterion in the phase II and III MIVI trials [1, 15] report but
was in the phase I trials [3]. We would suggest that myopia
greater than 8 dioptres and lattice degeneration should be con-
sidered as contraindications to OCP treatment. Whether
treating lattice preoperatively would reduce the risk of RRD
is unknown.
The median time to onset of RRD was 16 days after OCP
injection, with 37.5 % presenting within the first 7 days and
the rest presenting on days 14, 18, 20, 54, and 131. Photopsia
and floaters are common symptoms in the first few days after
OCP injection, and consistent with the action of the drug [5].
One of our cases presented whilst still symptomatic with
photopsia in the immediate postoperative period, while in four
cases there was recurrence of symptoms after the postopera-
tive symptoms had settled. Three of our cases, however, were
diagnosed whilst asymptomatic at routine review appoint-
ments. Our cases show that RRD post-OCP can be asymp-
tomatic, whilst others with symptoms may be difficult to dis-
tinguish from typical post OCP symptoms. We recommend
that scheduled appointments at the peak time of RRD in the
first few postoperative weeks, as well as careful peripheral
retinal examination at all visits, is important even if
asymptomatic.
Fig. 1 Diagrams of the rhegmatogenous retinal detachment cases showing associated retinal breaks and pathology
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There has been some speculation that breaks occurring
soon after ocriplasmin may have been a result of the physical
action of the intravitreal OCP injection in yielding vitreoretinal
traction [6]. This is supported by the fact that during the repair
of the retinal tear and detachment in the MIVI I trials, the
vitreous was found still firmly adherent to the retina [3]. In
our series, 3/7 presented with RRD within 7 days post-
injection; however, five cases presented 14–130 days post-
OCP. Given the timing of our five cases and one reported case
in the literature at 6 weeks post-OCP injection [7], and the fact
that VMT had released in all cases, makes OCP’s pharmaco-
logical action the likely culprit, rather than the physical action
of the intravitreal injection. It is important to note that although
26.5 % of OCP-injected eyes had vitreo-foveal separation in
the MIVI TRUST trials at day 28, complete PVD was noted in
only 13.4 % of eyes at the same time point. It is possible,
therefore, that more peripheral vitreous separation occurs later
in OCP-treated eyes, and the true incidence of tear and RRD
formation may ultimately be higher than during the limited
follow-up period carried out during the phase 3 studies. We
found complete PVD at the time of surgery in 88 % of cases,
and it’s clearly important to maintain vigilance for late com-
plete vitreous separation and consequent retinal tears.
Although OCP can induce a clean plane of vitreoretinal
separation [2, 16, 17] it does not appear to do this uniformly
across the whole VR interface. In a study characterising the
effect of OCP on the vitreoretinal interface in an ex-vivo por-
cine model, the vitreolytic effect was not found to be homog-
enous throughout the eye [18]. Retinal areas proximal to the
site of injection in the mid vitreous frequently appeared to be
more devoid of vitreous elements in comparison to more an-
terior areas. The authors concluded that although this may in
part reflect a difference in chemical structure of the vitreous
adjacent to the vitreous base, it might reflect a lack of exposure
to the enzyme that has to diffuse further to this particular
location from its site of injection. This raises the question as
to whether other factors, such as variable diffusion through the
vitreous and variations in drug preparation and injection tech-
nique, might also influence the effect of the drug with its short
half-life [19]. The distribution of retinal breaks would also
concur with this, in that the breaks were not concentrated in
the superotemporal quadrant as found in spontaneous PVD-
related tears and RRD [20]. Spontaneous PVD is thought to
occur perifoveally and extends first superiorly [21]. Surgically
induced vitreous separation results in a different retinal break
distribution to spontaneous PVD, with a more evenly distrib-
uted tear distribution or possibly a higher incidence of tears
inferiorly [22–24]. It is debated whether intravitreal injection
of OCP should be performed with more pressure or deeper
into the vitreous cavity than vascular endothelial growth factor
inhibitors [12]. In our series, OCPwas administered according
to the label, without interruption of the freezing cycle and
using a standard 30-gauge needle. The depth and site of
injection was not recorded, but no complications immediately
following injection were noted. It is possible that OCP-
mediated vitreous liquefaction can result in an incomplete
PVD leaving residual vitreous cortex attached to the retina
peripherally, ultimately contributing to late retinal break for-
mation [25].
We asked that surgeons report all cases of retinal tears and
RRD to us, but interestingly there were no cases of tears with-
out RRD reported. This is unusual, as it is known that not all
tears associated with spontaneous vitreous separation progress
to RRD [26]. There have been many reports of subretinal fluid
accumulation at the fovea after OCP, and Willekens et al.
reported this in 37 % of cases treated including peripapillary
SRF in some cases [7]. Increase in MH base diameter has also
been widely reported [5, 14, 27]. The aetiology of this is
unknown. There is plausible evidence that OCP causes weak-
ening of retinal adhesion by degrading laminin and possibly
other proteins in the outer retinal layers including the
interphotoreceptor matrix [28], which is known to mediate
retinal pigment epithelial-photoreceptor adhesion in primate
eyes [29]. This mechanism might also mean that tear forma-
tion has a higher incidence of progression to RRD after OCP
than after spontaneous PVD. Interestingly, in Pierson syn-
drome, which is caused by mutations in the laminin b2 gene,
the incidence of RRD is higher [30]. This provides further
evidence that laminin function is important for maintaining
retinal attachment, and perhaps tears induced after PVD from
OCP are more prone to progress to RRD.
There are several weaknesses to this study, in particular the
absence of a clear denominator number for the number of
cases treated in total with OCP that subsequently resulted in
the eight retinal detachments. We therefore do not know the
true incidence of RRD after OCP in our population. The study
was retrospective, and the follow-up after injection was at the
discretion of the treating specialist. There is therefore some
uncertainty of the timing of retinal detachment in some of the
cases.
Conclusion
RRD can occur after OCP injection, and patients should be
counselled preoperatively regarding the non-negligible risk of
RRD.We would recommend that OCP is used with caution in
eyes with greater than 8 dioptres of myopia and peripheral
retinal pathology predisposing to RRD, including lattice de-
generation. We would recommend that clinicians perform de-
tailed peripheral retinal inspections preoperatively and at
planned regular post-injection clinic visits. Furthermore, pa-
tients should be advised to seek attention if symptoms recur
after the immediate perioperative period. It is possible that the
real-world incidence of RRD with less strict exclusion criteria
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and longer follow-up will be higher than in the phase 3 trials,
and a further ongoing study is needed.
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